144 related articles for article (PubMed ID: 21051912)
21. Isolated loss of hormonal receptors in leptomeningeal metastasis from estrogen receptor- and progesterone receptor-positive lobular breast cancer.
Grewal J; Zhou H; Factor R; Kesari S
J Clin Oncol; 2010 May; 28(13):e200-2. PubMed ID: 20124173
[No Abstract] [Full Text] [Related]
22. Long-term follow-up results of breast cancer patients with sentinel lymph node biopsy using periareolar injection.
Imasato M; Shimazu K; Tamaki Y; Taguchi T; Tanji Y; Kim SJ; Noguchi S
Am J Surg; 2010 Apr; 199(4):442-6. PubMed ID: 19596117
[TBL] [Abstract][Full Text] [Related]
23. Management of inflammatory breast cancer after neoadjuvant chemotherapy.
Abrous-Anane S; Savignoni A; Daveau C; Pierga JY; Gautier C; Reyal F; Dendale R; Campana F; Kirova YM; Fourquet A; Bollet MA
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1055-63. PubMed ID: 20478662
[TBL] [Abstract][Full Text] [Related]
24. Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy.
Lee DS; Kim SH; Suh YJ; Kim S; Kim HK; Shim BY
Jpn J Clin Oncol; 2011 Jul; 41(7):854-66. PubMed ID: 21719749
[TBL] [Abstract][Full Text] [Related]
25. [Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
Mátrai Z; Tóth L; Polgár C; Láng I; Gõdény M; Sinkovics I; Horváth Z; Bidlek M; Udvarhelyi N; Bartal A; Sávolt A; Ujhelyi M; Kásler M
Magy Onkol; 2011 Jun; 55(2):73-84. PubMed ID: 21655472
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management.
Warren LE; Guo H; Regan MM; Nakhlis F; Yeh ED; Jacene HA; Hirshfield-Bartek J; Overmoyer BA; Bellon JR
Ann Surg Oncol; 2015 Aug; 22(8):2483-91. PubMed ID: 25791789
[TBL] [Abstract][Full Text] [Related]
28. What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach.
Yeh ED; Jacene HA; Bellon JR; Nakhlis F; Birdwell RL; Georgian-Smith D; Giess CS; Hirshfield-Bartek J; Overmoyer B; Van den Abbeele AD
Radiographics; 2013; 33(7):2003-17. PubMed ID: 24224593
[TBL] [Abstract][Full Text] [Related]
29. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
[TBL] [Abstract][Full Text] [Related]
30. MRI findings of inflammatory breast cancer, locally advanced breast cancer, and acute mastitis: T2-weighted images can increase the specificity of inflammatory breast cancer.
Uematsu T
Breast Cancer; 2012 Oct; 19(4):289-94. PubMed ID: 22351245
[TBL] [Abstract][Full Text] [Related]
31. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
32. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer and neoadjuvant therapy: any predictive marker?
Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
[TBL] [Abstract][Full Text] [Related]
34. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory breast cancer: the disease, the biology, the treatment.
Robertson FM; Bondy M; Yang W; Yamauchi H; Wiggins S; Kamrudin S; Krishnamurthy S; Le-Petross H; Bidaut L; Player AN; Barsky SH; Woodward WA; Buchholz T; Lucci A; Ueno NT; Cristofanilli M
CA Cancer J Clin; 2010; 60(6):351-75. PubMed ID: 20959401
[TBL] [Abstract][Full Text] [Related]
36. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
[TBL] [Abstract][Full Text] [Related]
37. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
[TBL] [Abstract][Full Text] [Related]
38. [Prevalence of male breast cancer in our department during a 5-year period].
Cseh I; Kerekes M; Solymosi T
Magy Seb; 2011 Jun; 64(3):112-5. PubMed ID: 21672681
[TBL] [Abstract][Full Text] [Related]
39. [Diagnosis and treatment of occult breast cancer: report of 23 cases].
Zhong Y; Sun Q; Huang HY; Zhou YD; Guan JH; Mao F; Lin Y; Xu YL
Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):716-8. PubMed ID: 21122392
[TBL] [Abstract][Full Text] [Related]
40. [Pharmaceutical therapy of breast cancer].
Láng I; Kahán Z; Pintér T; Dank M; Boér K; Pajkos G; Faluhelyi Z; Pikó B; Eckhardt S; Horváth Z
Magy Onkol; 2010 Sep; 54(3):237-54. PubMed ID: 20870601
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
